Clinical Trial Update: To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the objective response rate of four cycles of docetaxel plus an anthracycline (epirubicin or doxorubicin) followed by four cycles o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Doxorubicin (doxorubicin)
• Epirubicin (epirubicin)

Snippet

Sponsor: Sanofi | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED